Results 31 to 40 of about 22,562,840 (346)
Haemophilia, 2020 The development of an anti‐FVIII inhibitor is the most serious complication of haemophilia A occurring in up to 30% of severe haemophilic patients.
B. Polack +5 more
semanticscholar +1 more source
The history and evolution of the clinical effectiveness of haemophilia type a treatment: a systematic review. [PDF]
, 2012 First evidence of cases of haemophilia dates from ancient Egypt, but it was when Queen Victoria from England in the 19th century transmitted this illness to her descendants, when it became known as the "royal disease".
A Aleem +48 more
core +2 more sources
Research and Practice in Thrombosis and Haemostasis, 2019 Background Thrombin generation assay (TGA) and thrombelastography (TEG) are increasingly employed, global, in vitro methods for assessment of the procoagulant potential of plasma/blood and possibly ideally suited tools to monitor, for example, therapy ...
Egon Persson, Mette Winther
doaj +1 more source
International consensus recommendations on the management of people with haemophilia B
Therapeutic Advances in Hematology, 2022 Haemophilia B is a rare X-linked genetic deficiency of coagulation factor IX (FIX) that, if untreated, can cause recurrent and disabling bleeding, potentially leading to severe arthropathy and/or life-threatening haemorrhage.
Daniel P. Hart +14 more
doaj +1 more source
Haemophilia and joint disease: pathophysiology, evaluation and management [PDF]
, 2011 In patients with haemophilia, regular replacement therapy with clotting factor concentrates (prophylaxis) is effective in preventing recurrent bleeding episodes into joints and muscles.
Berntorp, Erik, Knobe, Karin
core +3 more sources
Orphanet Journal of Rare Diseases, 2022 Background Haemophilia bears substantial humanistic and economic burden on children and their caregivers. Characterising the differential impact of severe versus moderate paediatric haemophilia is important for clinical and health policy decisions.
Idaira Rodriguez-Santana +6 more
doaj +1 more source
Preventing perioperative bleeding in patients with inherited bleeding disorders [PDF]
, 2017 Data sources: Cochrane Cystic Fibrosis and Genetic Disorders Group's Coagulopathies Trials Register, a regularly updated database informed by trials identified within electronic databases including MEDLINE.
Beacher, Nicholas, Watterson, Colin
core +1 more source
Global measurement of coagulation in plasma from normal and haemophilia dogs using a novel modified thrombin generation test - Demonstrated in vitro and ex vivo. [PDF]
PLoS ONE, 2017 Canine models of severe haemophilia resemble their human equivalents both regarding clinical bleeding phenotype and response to treatment. Therefore pre-clinical studies in haemophilia dogs have allowed researchers to make valuable translational ...
Daniel Elenius Madsen +4 more
doaj +1 more source
Inhibitors in Patients with Congenital Bleeding Disorders Other Than Hemophilia [PDF]
, 2017 The most worrying complication of replacement therapy for severe hemophilia A and B is currently the occurrence of inhibitory alloantibodies against infused factor VIII and factor IX, respectively.
Franchini, Massimo +6 more
core +1 more source
Haemophilia A and haemophilia B: molecular insights [PDF]
Molecular Pathology, 2002 This review focuses on selected areas that should interest both the scientist and the clinician alike: polymorphisms within the factor VIII and factor IX genes, their linkage, and their ethnic variation; a general assessment of mutations within both genes and a detailed inspection of the molecular pathology of certain mutations to illustrate the ...
openaire +6 more sources